Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end
Open Access
- 26 May 2025
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-17
Abstract
Albumin has a long plasma half-life due to engagement of the neonatal Fc receptor (FcRn), which prevents intracellular degradation. However, its C-terminal end can be cleaved by carboxypeptidase A, and removal of the last leucine residue (L585) weakens receptor binding, reducing its half-life from 20 days to 3.5 days in humans. This biology has so far been overlooked when designing human albumin-fused biologics. Thus, there is a need for an engineering strategy to secure favorable FcRn binding and pharmacokinetic properties. Here, we show that a branched aliphatic amino acid or methionine at position 585 of albumin is required for optimal receptor binding, which cannot be replaced to prevent enzymatic cleavage without negatively affecting FcRn engagement. As a solution, we report that C-terminally cleaved albumin can be efficiently rescued from intracellular degradation by introducing amino acid substitutions that improve FcRn binding. This albumin-engineering strategy was also effective when applied with a therapeutic fusion partner, glucagon-like peptide 1 (GLP-1), resulting in a 2-fold increase in plasma half-life and prolonged efficacy in human FcRn transgenic mice. We demonstrate how human albumin fusions should be tailored to ensure a long plasma half-life and enhanced efficacy of fused biologics, despite potential C-terminal cleavage in vivo.Keywords
Funding Information
- Norges Forskningsråd (332727, 274993, 287927, 285136)
- Ministry of Health and Care Services | Helse Sør-Øst RHF (2018052, 2024046, 2019084)
This publication has 100 references indexed in Scilit:
- Human serum albumin presents isoform variants with altered neonatal Fc receptor interactionsProtein Science, 2019
- gPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug developmentJournal of Pharmacokinetics and Pharmacodynamics, 2018
- Enteroendocrine K and L cells in healthy and type 2 diabetic individualsDiabetologia, 2017
- Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal ImpairmentClinical Pharmacokinetics, 2017
- Mouse Models of Type 2 Diabetes Mellitus in Drug Discovery2016
- Albiglutide: First Global ApprovalDrugs, 2014
- Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activityDiabetologia, 1998
- Vitamin K-dependent carboxylase: Influence of the “propeptide” region on enzyme activityArchives of Biochemistry and Biophysics, 1989
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987
- Recognition site directing vitamin K-dependent γ-carboxylation resides on the propeptide of factor IXCell, 1987